Altimmune Inc  

(Public, NASDAQ:ALT)   Watch this stock  
Find more results for ALT
0.00 (0.00%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.63 - 35.00
Open     -
Vol / Avg. 0.00/93,411.00
Mkt cap 38.47M
P/E 0.09
Div/yield 29.10
EPS 29.11
Shares 15.45M
Beta 1.74
Inst. own 19%
May 11, 2017
Q1 2017 PharmAthene Inc Earnings Release (Estimated)
May 4, 2017
PharmAthene Inc Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -273.31% 3706.44%
Operating margin -395.90% -215.37%
EBITD margin - -212.63%
Return on average assets -7.18% 158.51%
Return on average equity -47.00% 1073.74%
Employees 13 -
CDP Score - -


19 Firstfield Rd
United States - Map
+1-240-6541450 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.

Officers and directors

David J. Drutz M.D. Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
William Enright President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Elizabeth A. Czerepak Chief Financial Officer, Executive Vice President - Corporate Development
Age: 61
Bio & Compensation  - Reuters
Sybil Tasker M.D. Senior Vice President - Clinical Research and Development
Bio & Compensation  - Reuters
M. Scot Roberts Ph.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Philip L. Hodges Director
Bio & Compensation  - Reuters
Mitchel B. Sayare Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Klaus O. Schafer M.D. Director
Bio & Compensation  - Reuters
Derace L. Schaffer M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters